Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

T-Cell Engager Set For Pivotal GI Trial

 
• By Dexter Jie Yan
  
The CDH17 race has been becoming tighter since 2022, when Arbele took its first candidate against the target into the clinic. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Interviews

More from Focus On Asia